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Ras and pRb are key regulators of a plethora of cellular processes, including proliferation, differentiation, and
tumorigenesis. Adding to several previously established lines of communication between the two, in this
issue of Cancer Cell, Shamma et al. resolve a new signaling network involved in cellular senescence and
tumor suppression.The ras family of proto-oncogenes and
the retinoblastoma tumor suppressor
gene, Rb, have been the subjects of thou-
sands of studies, yet not all of their
secrets have been revealed. The general
message emanating from these studies
is that each gene acts as a key regulator
of several cellular processes, most
notably proliferation and differentiation.
Most likely as a consequence of these
involvements, they also correspond to
common human cancer genes, with ras
frequently acting as an oncogene upon
activation by point mutation and Rb rep-
resenting a classical tumor suppressor
gene contributing to cancer upon (func-
tional) loss of both of its alleles. Ras
resides near the cell membrane, where it
transduces extracellular signals through
various cascades to the nucleus. pRb is
a nuclear protein that regulates prolifera-
tion and differentiation by controlling tran-
scriptional programs, at least in part by
engaging in physical interactions with
transcription factors like E2Fs, MyoD,
and C/EBPb.
In spite of their geographical distance,
intimate communication takes place
between Ras and pRb, through various
signaling channels. First, pRb acts as
a critical effector for Ras. Specifically,
whereas Ras activity is required for
progression through the G1 phase of
the cell cycle in normal mouse embryo
fibroblasts, Rb-deficient cells continue
to divide irrespective of Ras activity
(Peeper et al., 1997). Second, their
communication is bidirectional: in turn,
Ras activity is regulated as a function
of pRb (Figure 1A). Rb deficiency sharply
increases the ability of Ras to bind
guanine nucleotides, resulting in the
activation of the latter (Lee et al.,1999). Third, in addition to this mutual
negative feedback loop, a genetic inter-
action between Ras and the C. elegans
ortholog of Rb has been shown to
underlie vulval cell fates (Lu and Horvitz,
1998).
In the mouse, work from Ewen and
coworkers in particular has revealed
strong genetic interactions between these
factors (Figure 1B). During embryogen-
esis, inactivation of N-ras rescues several
developmental defects incurred by Rb
loss (Takahashi et al., 2003). Furthermore,
heterozygosity for either N-ras or one of
its cousins, K-ras, reduces the expansion
of pituitary adenocarcinomas in Rb+/
mice, thereby prolonging survival
(Takahashi et al., 2004). In contrast, in
another tumor setting, thyroid C cell
adenomas, deficiency for N-ras in the
context of Rb loss allows tumors to
acquire metastatic potential (Takahashi
et al., 2006), indicating that the role of
N-ras in the context of Rb loss-driven
carcinogenesis is cell type dependent.
What has emerged from these and
other studies is a complex interplay
between Ras and pRb, impacting on
proliferation, differentiation, develop-
ment, tumorigenesis, and metastasis. As
always, these studies have triggered
new questions. Most notably, although
a corner of the veil has been lifted, it has
remained unclear exactly how the
intimate communication between these
two proteins is relayed. In this issue of
Cancer Cell, Takahashi and colleagues
unmask an unanticipated mechanism by
which Ras and pRb functionally interact
(Shamma et al., 2009). They also portray
a physiological setting, cellular senes-
cence, in which this new type of commu-
nication is highly relevant.Cancer CSenescence can be elicited by various
cellular stress conditions, including the
unscheduled activation of oncogenes and
the inactivationof tumorsuppressorgenes.
Whereas it was initially considered
a phenomenon limited to cells in culture,
over the past five years, several laborato-
rieshavedemonstrated that, in fact, ‘‘onco-
gene-induced senescence’’ (OIS, a collec-
tive term) acts next to various cell death
programs, constituting a strong and sepa-
rate line of defense against cancer (Prieur
and Peeper, 2008). OIS operates during
early tumorigenesis and involves the
activation of several tumor suppressor
networks, including the p16INK4A/pRb and
ARF/p53 pathways. They keep incipient
tumor cells in check and thereby prevent
themfromprogressing towardmalignancy.
Shamma et al. (2009) studied the
progression of murine Rb-deficient C
cell adenoma to adenocarcinoma. As
already mentioned, this group had
shown previously that, whereas loss of
both Rb alleles is required for onset of
the adenomas, inactivation of both N-ras
alleles causes malignant conversion and
metastasis. In their current paper, they
show that loss of N-Ras expression is
associated with increased proliferative
activity. A steep drop in several DNA
damage-associated specific phosphory-
lation events involving histone H2AX,
ATM kinase, and p53 accompanied the
conversion from adenoma to adenocarci-
noma. Interestingly, N-ras-proficient
(Rb-deficient) adenomas displayed several
markers of cellular senescence such as
elevated expression of histoneH3 trimethy-
lated at lysine 9 (H3K9me3), heterochro-
matin protein 1g (HP1g), and p16Ink4a and
increasedsenescence-associatedb-galac-
tosidase activity. These markers wereell 15, April 7, 2009 ª2009 Elsevier Inc. 243
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Figure 1. Interactions between N-Ras and pRb in Cell-Cycle Control, Development,
Senescence, and Cancer
(A) Ras proteins, including N-Ras, and pRb communicate during cell-cycle progression through mutual
negative feedback loops. Ras activation leads to pRb inactivation in a cyclin D-dependent manner.
Conversely, Rb deficiency results in elevated Ras activity.
(B) In vivo, loss of N-ras rescues developmental defects resulting from Rb deficiency, thereby extending
life span. At the same time, N-ras loss reduces aggressiveness of pituitary tumors. In contrast, combined
deficiency for N-ras and Rb results in metastatic thyroid C cell adenocarcinomas.
(C) Shamma et al. (2009) demonstrate the existence of a pathway from pRb back to N-Ras, in which the
latter is activated upon loss of the first through E2F- and SREBP-dependent stimulation of prenylation.
Subsequently, activated N-Ras triggers a DNA damage response and cellular senescence, thereby block-
ing C cell carcinogenesis driven by Rb deficiency.largely absent in proliferating N-ras-defi-
cient adenocarcinomas.
OIS is sometimes associated with DNA
hyperreplication and a DNA damage
response (DDR) (Campisi and d’Adda di
Fagagna, 2007). However, the relative
kinetics of these processes are largely
unclear. Shamma et al. effectively ex-
ploited the opportunity offered by their
model system to look into this important
issue. Monitoring various markers in early
(6months) and late (11months) adenomas,
they observed little difference in the
expression patterns of DNA damage
markers. In contrast, senescence markers
were expressed at lower levels in early
adenomas than in late adenomas. As
expected, this was inversely correlated
with the adenomas’ proliferative capacity.
A likely interpretation of these results is
that, at least in this experimental model,
a DDR is insufficient (or perhaps not even
required) to boost a cytostatic response,
and it is the senescence program that244 Cancer Cell 15, April 7, 2009 ª2009 Elseis responsible for the cell-cycle arrest
of these adenomas. Shamma et al.
confirmed the latter idea by a series of
genetic inactivation experiments demon-
strating a causal role for the senescence-
associated genes Ink4a, Arf, and Suv39h1
in antagonizingRb-deficientCcell carcino-
genesis.
These results suggest a model in which
N-Ras proteins, in response to Rb defi-
ciency, protect C cells from progressing
to malignancy. This predicts that N-Ras
somehow affects cell-cycle progression.
Indeed, when Shamma et al. restored
N-Ras expression in Rb/N-ras-deficient
thyroid tumor cells established in culture,
they elicited both a DDR and a senes-
cence response. Reconstituted expres-
sion of pRb abolished the ability of
N-Ras to induce senescence.
How, then, is N-Ras activated in
response to pRb loss? The investigators
noted that when reintroduced into these
cells, pRb suppressed transcription ofvier Inc.farnesyl diphosphate synthase (Fdps) and
sterol regulatory element-binding protein
(SREBP)-encoding genes as well as
several of their effector genes, including
prenyltransferases, in an E2F-dependent
fashion. Correspondingly, SREBP-1 and
-2 expression was increased in murine
C cell adenomas. In keeping with this,
it was shown that pRb deficiency
increased N-Ras isoprenylation under
certain conditions, leading to its activation
and subsequent induction of senescence.
Confirming this model, an isoprenylation-
deficient N-Ras mutant failed to trigger
a DDR and senescence, whereas treat-
ment with prenyltransferase inhibitors
suppressed these responses. Extrapo-
lating these results to the human situation,
negative immunostaining for pRb coin-
cided with low levels of N-Ras in several
sporadic medullary thyroid carcinomas,
consistent with a requirement of N-Ras
suppression during tumor progression
initiated by Rb loss.
The work of Shamma et al. unmasks an
original mechanism for the functional
interaction between N-Ras and pRb in
the context of a tumor progression model
and resolves a signaling network in which
genetic inactivation of Rb releases E2Fs
to induce a wave of farnesylation. Modi-
fied proteins include N-Ras, which as
a result mounts robust DNA damage and
senescence responses (Figure 1C). These
results also explain why selection can
occur against N-ras in Rb-deficient
tumors and, as such, offer a rationale for
the previously noted tumor suppressor
function of Ras (Zhang et al., 2001 and
references therein). Whether these results
also bear on novel clinical entry points,
as the authors predict, remains to be
determined.
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Androgen signaling is critical for pro
androgen deprivation therapies. A s
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Prostate cancer (PCa) is the most
frequently diagnosed cancer and the
second leading cause of cancer-related
death in Western men. Since the recogni-
tion of PCa as an androgen-sensitive
disease in 1941, androgen deprivation
strategies have been the principal treat-
ment option for non-organ-confined PCa
or PCa that recurs after initial surgery or
radiation therapy. Androgen deprivation
therapies (ADTs) target the action of the
androgen receptor (AR), the transcription
factor mediating the cellular effects of
androgens, by reducing the circulating
levelsof itsnatural ligandsand/orbyadmin-
istration of antiandrogens that compete for
binding to the AR. Following initial remis-
sion, most PCas recur after ADT, giving
rise to castration-recurrent PCa (CRPC),
which is almost invariably lethal. Evidence
from basic research and clinical studies
indicates that the AR and AR-dependent
transcriptional program remain activated
in CRPC (Chen et al., 2008; Debes and Tin-
dall, 2004; Mohler, 2008). This unexpected
reactivation of the AR inCRPC,whichhigh-
lights its validity as a therapeutic target also
in CRPC, has been attributed toARamplifi-
cations, gain-of-function mutations of the
AR,andchanges in theactivityof regulatorsTakahashi, C., Contreras, B., Bronson, R.T., Loda,
M., and Ewen, M.E. (2004). Mol. Cell. Biol. 24,
10406–10415.
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liferation of prostate cancer cells bu
tudy by Xu et al. in this issue of Ca
g in prostate cancer and sugges
and signal transduction pathways that
modulate AR activity. More recently, find-
ings of local, intratumoral production of
androgens in CRPC at levels sufficient to
activate the AR have led to therapeutic
approaches targeting in situ androgen
biosynthesis (Attard et al., 2008; Mohler,
2008).While initial results from such clinical
trials are encouraging, they also under-
score the continued reliance of PCa on AR
activation and the resourcefulness of PCa
cells in evading ADT strategies. In-depth
knowledge of the molecular mechanisms
by which the AR regulates transcription of
target genes that are critical toPCadisease
may offer the rationale to design thera-
peutic alternatives targeting this critical
regulator of PCa cell growth.
The AR is a member of the nuclear
receptor superfamily of ligand-activated
transcription factors. Its mechanism of
action resembles that of other members of
the steroid hormone receptor family. In the
classical model of AR action, binding of
androgens causes an inactive cytoplasmic
AR to undergo a change in conformation,
homodimerization, and relocation to the
nucleus. There, the activated AR binds to
specific recognition sequences known as
androgen-responsive elements (AREs)
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ts avenues to target a subset of
located in or near androgen-regulated
genes where it recruits the coregulators
and the basal transcriptional machinery
necessary to assemble a productive tran-
scriptional complex and ultimately affect
the transcription of target genes (Heemers
and Tindall, 2007).
Over a decade of screening has identi-
fied approximately 200 proteins that
interact with the AR and collaborate with it
to execute its transcriptional program. At
the same time, systems and bioinformatics
approaches have identified hundreds of
androgen-regulated genes and character-
ized genome-wide AR recruitment sites in
PCa cells. The combined knowledge
gained from these studies is starting to
reveal a picture of daunting complexity
underlying the activity of the AR transcrip-
tional complex that far exceeds the
simplicity of traditionalmodels of androgen
action.
Apart fromgeneral transcription factors,
proteins recruited to DNA-bound AR can
be divided into two classes: coregulators
and specific transcription factors that
interact with their consensus binding
elements (Heemers and Tindall, 2007).
The former class consists of proteins that
associate either directly or indirectly with
ell 15, April 7, 2009 ª2009 Elsevier Inc. 245
